Wells Fargo & Company Viracta Therapeutics, Inc. Put Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding VIRX
# of Institutions
41Shares Held
5.63MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$212,8330.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA954KShares$133,6270.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$96,5590.09% of portfolio
-
Stonepine Capital Management, LLC Bend, OR500KShares$70,0000.07% of portfolio
-
Laurion Capital Management LP New York, NY332KShares$46,5060.0% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $5.26M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...